11/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/17
07:10 am
sabs
Rating for SABS
Medium
Report
Rating for SABS
9/19
12:31 pm
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
9/19
11:57 am
sabs
Rating for SABS
Medium
Report
Rating for SABS
9/17
08:15 am
sabs
Rating for SABS
High
Report
Rating for SABS
9/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
9/17
06:58 am
sabs
SAB Biotherapeutics initiated with an Outperform at Leerink
High
Report
SAB Biotherapeutics initiated with an Outperform at Leerink